Alnylam: Encouraging Results From Phase 2 Cemdisiran Study in IgA Nephropathy
June 09 2022 - 7:09AM
Dow Jones News
By Michael Dabaie
Alnylam Pharmaceuticals Inc. said that results were positive
from the Phase 2 study of cemdisiran for immunoglobulin A
nephropathy, and that it is planning for Phase 3 development.
At Week 32, treatment with cemdisiran resulted in a 37% mean
reduction from baseline in the 24-hour urine protein to creatinine
ratio relative to placebo. The company said this was the primary
objective of the study and an important marker of disease
progression.
IgAN is the most common inflammatory disease affecting the
glomerulus of the kidney often progressing to kidney failure,
Alnylam said.
Alnylam said cemdisiran is in development in collaboration with
Regeneron Pharmaceuticals Inc.
The results of secondary endpoints were also consistent with a
therapeutic benefit of cemdisiran in IgAN, the company said. There
were no significant drug-related safety signals.
The company said the efficacy and safety data support continued
clinical development of cemdisiran monotherapy in patients with
IgAN.
"Given the limited treatment options and significant unmet need
in IgAN, we, together with our partners at Regeneron, are
formulating our plans for the Phase 3 clinical development of
cemdisiran," Sonalee Agarwal, vice president and program leader for
the cemdisiran program at Alnylam, said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
June 09, 2022 07:54 ET (11:54 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Apr 2024 to May 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From May 2023 to May 2024